Mollugin
Mollugin may be a JAK2 inhibitor and inhibits LPS-induced inflammatory responses by blocking the activation of the JAK-STAT pathway. Mollugin as a candidate for a chemotherapeutic agent in OSCCs via the upregulation of the HO-1 and Nrf2 pathways and the downregulation of NF- κ B. Mollugin may be a novel therapeutic candidate for bone loss-associated disorders including osteoporosis, rheumatoid arthritis, and periodontitis. Also, it has anticancer efficacy, can modulate the HER2 pathway in HER2-overexpressing Y cells with a potential role in the treatment and prevention of human breast and ovarian Y with HER2 overexpression.
Product Specifications
CAS Number
55481-88-4
Product Name Alternative
Rubimaillin | Mollugin
Purity
>98% (HPLC)
Solubility
In Vitro: DMSO : 33.33 mg/mL (117.23 mM)
Smiles
CC1 (C=Cc2c (O1) c1ccccc1c (c2C (=O) OC) O) C
Molecular Formula
C17H16O4
Molecular Weight
284.3
Storage Conditions
Storage temperature: -20°C. Stability: ≥ 2 years
Notes
For research use only.
Other Product Names
Methyl 6-hydroxy-2,2-dimethyl-2H-benzo[h]chromene-5-carboxylate
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
Lentiviral mouse Pcsk7 shRNA (UAS) - Lentiviral mouse Pcsk7 shRNA (UAS, iRFP) (100)